CANC vs. HRTS

Last updated Apr 1, 2026

Compare and contrast key facts about Tema Oncology ETF (CANC) and Tema Obesity & Cardiometabolic ETF (HRTS).

CANC and HRTS are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. CANC is an actively managed fund by Tema. It was launched on Aug 14, 2023. HRTS is an actively managed fund by Tema. It was launched on Nov 20, 2023.

Performance

CANC vs. HRTS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tema Oncology ETF (CANC) and Tema Obesity & Cardiometabolic ETF (HRTS). The values are adjusted to include any dividend payments, if applicable.

CANC vs. HRTS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
CANC Tema Oncology ETF	5.69%	42.92%	-5.37%	16.21%
HRTS Tema Obesity & Cardiometabolic ETF	-4.55%	23.93%	-4.30%	14.97%

Returns By Period

In the year-to-date period, CANC achieves a 5.69% return, which is significantly higher than HRTS's -4.55% return.

CANC

• 1D: 4.66%
• 1M: -2.88%
• YTD: 5.69%
• 6M: 27.93%
• 1Y: 52.46%
• 3Y*: 140.00%
• 5Y*: —
• 10Y*: —

HRTS

• 1D: 2.94%
• 1M: -6.67%
• YTD: -4.55%
• 6M: 10.36%
• 1Y: 16.44%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CANC vs. HRTS - Expense Ratio Comparison

Both CANC and HRTS have an expense ratio of 0.75%.

CANC

Tema Oncology ETF

HRTS

Tema Obesity & Cardiometabolic ETF

Return for Risk

CANC vs. HRTS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CANC

CANC Risk / Return Rank: 90
CANC Sharpe Ratio Rank: 89
CANC Sortino Ratio Rank: 90
CANC Omega Ratio Rank: 82
CANC Calmar Ratio Rank: 94
CANC Martin Ratio Rank: 93

HRTS

HRTS Risk / Return Rank: 47
HRTS Sharpe Ratio Rank: 47
HRTS Sortino Ratio Rank: 47
HRTS Omega Ratio Rank: 41
HRTS Calmar Ratio Rank: 57
HRTS Martin Ratio Rank: 44

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CANC vs. HRTS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tema Oncology ETF (CANC) and Tema Obesity & Cardiometabolic ETF (HRTS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CANC	HRTS	Difference
Sharpe ratio Return per unit of total volatility	1.94	0.86	+1.08
Sortino ratio Return per unit of downside risk	2.59	1.27	+1.32
Omega ratio Gain probability vs. loss probability	1.32	1.16	+0.16
Calmar ratio Return relative to maximum drawdown	3.86	1.44	+2.42
Martin ratio Return relative to average drawdown	13.76	4.11	+9.65
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CANC vs. HRTS - Sharpe Ratio Comparison

The current CANC Sharpe Ratio is 1.94, which is higher than the HRTS Sharpe Ratio of 0.86. The chart below compares the historical Sharpe Ratios of CANC and HRTS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CANC	HRTS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.94	0.86	+1.08
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	0.62	-0.66

Correlation

The correlation between CANC and HRTS is 0.82, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.

Dividends

CANC vs. HRTS - Dividend Comparison

CANC's dividend yield for the trailing twelve months is around 0.05%, less than HRTS's 1.40% yield.

	TTM	2025	2024	2023
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%
HRTS Tema Obesity & Cardiometabolic ETF	1.40%	1.34%	1.63%	0.00%

Drawdowns

CANC vs. HRTS - Drawdown Comparison

The maximum CANC drawdown since its inception was -97.53%, which is greater than HRTS's maximum drawdown of -25.81%. Use the drawdown chart below to compare losses from any high point for CANC and HRTS.

Drawdown Indicators

	CANC	HRTS	Difference
Max Drawdown Largest peak-to-trough decline	-97.53%	-25.81%	-71.72%
Max Drawdown (1Y) Largest decline over 1 year	-12.40%	-11.01%	-1.39%
Current Drawdown Current decline from peak	-56.19%	-8.03%	-48.16%
Average Drawdown Average peak-to-trough decline	-73.91%	-9.12%	-64.79%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.61%	3.86%	-0.25%

Volatility

CANC vs. HRTS - Volatility Comparison

Tema Oncology ETF (CANC) has a higher volatility of 8.36% compared to Tema Obesity & Cardiometabolic ETF (HRTS) at 5.96%. This indicates that CANC's price experiences larger fluctuations and is considered to be riskier than HRTS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CANC	HRTS	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.36%	5.96%	+2.40%
Volatility (6M) Calculated over the trailing 6-month period	16.34%	11.22%	+5.12%
Volatility (1Y) Calculated over the trailing 1-year period	27.24%	19.25%	+7.99%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	285.66%	19.28%	+266.38%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	285.66%	19.28%	+266.38%